Vitamin C Deficiency in Septic Shock

NCT ID: NCT06224881

Last Updated: 2024-01-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-01

Study Completion Date

2023-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objectives: investigators aim to study the effect of addition of vitamin C as a part of treatment in septic shock patients on: Hemodynamics, Inflammation status and ICU outcome.

Subjects and methods: A prospective interventional randomized cohort study, was conducted on 150 consecutive patients who were admitted to the ICU with septic shock based on SIRS, SOFA and APACHE II. Treatment group (n=75) had given ascorbic acid (Vitamin C) parenterally 6gm daily and control group (n=75). Measuring the level of Vitamin C in all study population (normal range 50-70 μM/L) before and after period of 4 days.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

AIM OF THE WORK investigators aim to study the effect of addition of vitamin C in septic shock patients on:

* Mean arterial pressure
* C-reactive protein as an inflammatory marker
* Vasopressors ( norepinephrine) dose and duration.
* ICU outcome ( ICU stay, 7 and 28 days mortality)

SUBJECTS AND METHODS

Study type A prospective interventional randomized cohort study carried out at Critical Care Department, Cairo University Hospitals with 25 ICU beds for medical and surgical patients, in the period between December 2021 to January 2023.

An informed consent from 1st degree relatives was taken and confidentiality of information was assured.

Permission from the faculty of medicine ethical committee was obtained. Ethical committee approval number: MS-362-2019

Study design of the study population The patients' demographic data (including age, sex, baseline diseases, and causes of ICU admission) were extracted from their medical charts, and the patients' clinical characteristics (such as vital signs and hemodynamic parameters) were monitored as daily interval.

Laboratory data such as serum electrolyte concentrations, serum creatinine levels were extracted from the patients' medical charts.

Vit C level was measured for all patients (normal range 50-70 μM/L).

The patients' Acute Physiology and Chronic Health Evaluation II (APACHE II) and sequential organ failure assessment (SOFA) scores were calculated at the time of admission.

Patients were randomly divided into 2 groups into:

A) Treatment group (n=75) B) Control group (n=75) Ascorbic acid (Vitamin C) was given parenterally for the treatment group (2 gm every 8hrs) for 4 days.

Remeasuring the level of Vitamin C in all study population after 4 days.

• Measurement and administration of Vitamin C Vitamin C (Ascorbic Acid) parenteral formula Manufacturer: Arco Life sciences ( Http://www.arcolifesciences.co.in/ ) Ampules: each ampule contains 500 mg of ascorbic acid (5 ml each 1 ml contains 100mg) The dose and duration of intervention were selected based on the literature review.

Each dose of ascorbic acid was diluted in 50 ml of dextrose 5% solution and was administered as intravenous infusion over 30 minutes.

During the study period, patients were followed for any ascorbic acid-related adverse effects including nausea, vomiting, abdominal pain, hematuria, flushing, and significant arterial blood pressure change.

Measurement Kits This kit is an Enzyme-Linked Immunosorbent Assay (ELISA). The plate has been pre-coated with human Vitamin C antibody (VC). VC present in the sample is added and binds to antibodies coated on the wells. Substrate solution is then added and color develops in proportion to the amount of human VC and absorbance is measured at 450 nm.

* Manufacturer Bioassay Technology Labs
* Serial number: E1538Hu
* Standard Curve Range: 200 Mg/ml - 300 Mg/ml
* Sensitivity: 0.52 Mg/ml
* Size: 96 wells
* Storage: Store the reagents at 2-8°C. For over 6-month storage refer to the expiration date keep it at -20°C. Avoid repeated thaw cycles. If individual reagents are opened it is recommended that the kit be used within 1 month.
* Specimen Collection Serum Allow serum to clot for 10-20 minutes at room temperature. Centrifuge at 2000-3000 RPM for 20 minutes Plasma Collect plasma using EDTA or heparin as an anticoagulant. Centrifuge samples for 15 minutes at 2000-3000 RPM at 2 - 8°C within 30 minutes of collection.
* Calculation of results :

Plasma vitamin C level were measured by Vitamin C ELISA Kits by microgram /milliliter (μg/ml) and calculated to micromole/ L (μM/L) in factor of 5.6679 and results were given accordingly

• Normal range of Vitamin C in plasma : Multiple ranges are given in the level of vitamin C but recent studies consider range of (50-70μ M/L) is the reference in patients with sepsis and septic shock .

Statistical analysis Analysis of data was done using Statistical Program for Social Science version 20 (SPSS Inc., Chicago, IL, USA). Quantitative variables were described in the form of mean and standard deviation. Qualitative variables were described as number and percent. In order to compare parametric quantitative variables between two groups, Student t test was performed. Qualitative variables were compared using chi-square (X2) test or Fisher's exact test when frequencies were below five. Pearson correlation coefficients were used to assess the association between two normally distributed variables. When a variable was not normally distributed, A P value \< 0.05 is considered significant The used tests were Chi-square test For categorical variables, to compare between different groups, Fisher's Exact or Monte Carlo correction for chi-square when more than 20% of the cells have expected count less than 5,Student t-test For normally distributed quantitative variables, to compare between two studied groups, ANOVA with repeated measures for normally distributed quantitative variables, to compare between more than two periods or stages, and Post Hoc test (Bonferroni adjusted) for pairwise comparisons, Pearson coefficient To correlate between two normally distributed quantitative variables, Mann Whitney test For abnormally distributed quantitative variables, to compare between two studied groups, Friedman test For abnormally distributed quantitative variables, to compare between more than two periods or stages and Post Hoc Test (Dunn's) for pairwise comparisons and Q: Cochran's test For non-parametric test for binary response variable and Post Hoc Test (Dunn's) for pairwise comparisons.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Septic Shock

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vitamin C group

Ascorbic acid (Vitamin C) was given parenterally (2 gm every 8hrs) for 4 days.

Group Type ACTIVE_COMPARATOR

Ascorbic acid

Intervention Type DRUG

2 gm every 8hrs for 4 days

Control group

No vit C given

Group Type PLACEBO_COMPARATOR

Ascorbic acid

Intervention Type DRUG

2 gm every 8hrs for 4 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ascorbic acid

2 gm every 8hrs for 4 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Septic shock (defined by sepsis induced hypotension i.e. MAP \< 65 mmHg, tissue hypo-perfusion, vasopressors

Exclusion Criteria

* Age below 18 years old
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mostafa Farouk

Lecturer of critical care

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mohamed Ashraf, MD

Role: STUDY_DIRECTOR

Cairo University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cairo university

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MS-362-2019

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ascorbic Acid (Vitamin C) Infusion in Human Sepsis
NCT01434121 COMPLETED PHASE1/PHASE2
Triple Therapy in Septic Shock Patients
NCT04508946 COMPLETED PHASE3